Craft

Statera Biopharma

Stock Price

$0

2024-10-29

Market Capitalization

$21.4 K

2024-10-29

Revenue

$1.5 M

FY, 2021

Statera Biopharma Summary

Company Summary

Overview
Statera Biopharma (formerly known as Cytocom) is a pre-clinical and clinical biopharmaceutical company that develops product candidates for treating diseases involving immune system dysfunction. It offers immunotherapies targeting autoimmune diseases and cytopenias, including thrombocytopenia, neutropenia, and anemia, as well as emerging viruses and cancers, based on a platform designed to rebalance the body’s immune system and restore homeostasis.
Type
Public
Status
Active
Founded
2003
HQ
Fort Collins, CO, US | view all locations
Website
https://www.staterabiopharma.com/
Cybersecurity rating
Sectors

Key People

  • Michael K. Handley

    Michael K. Handley, President, CEO & Chairman

  • Stephen Wilson

    Stephen Wilson, Chief Innovation Officer

  • Clifford Selsky

    Clifford Selsky, Chief Medical Officer

  • Robert W. Buckheit

    Robert W. Buckheit, Chief Technology Officer

    Operating MetricsView all

    Facility Space Leased, sq. ft.

    187

    FY, 2021

    LocationsView all

    2 locations detected

    • Fort Collins, CO HQ

      United States

      4333 Corbett Dr #1082

    • Fort Collins, CO

      United States

      2537 Research Blvd Suite 201

    Statera Biopharma Financials

    Summary Financials

    Revenue (Q3, 2022)
    $670.5K
    Gross profit (Q3, 2022)
    $501.1K
    Net income (Q3, 2022)
    ($3.4M)
    Cash (Q3, 2022)
    $506.1K
    EBIT (Q3, 2022)
    ($1.5M)
    Enterprise value
    $6.9M

    Footer menu